RE:RE:RE:Biotech industry readies for " Pharma M&A Spree" November 19, 2024 - For “almost three years now” deal making has been a challenge across the life sciences industry, said Ed Saltman, senior strategic advisor at consultancy firm Lumanity, described to the audience at Bio Europe in Stockholm, Sweden.
He outlined three points he believes are the “biggies” to shape the conversation. Number one, “pharma needs to rely on biotech for innovation. We are not going to challenge that one, anyone who wants to challenge that one I would love to have that argument [because] you will not win.”
Number two concerned the “loss of exclusivity,” and number three detailed how “pharma greatly prefers late-stage assets over anything else.” To conclude his opening remarks, Saltman added that “all of these things have been given as fundamental to deal making since it began decades and decades ago.”